The measurement of biomarker expression levels has been successfully employed for selecting patients for monoclonal antibody-based targeted therapy, as in the treatment with trastuzumab (anti-HER2 humanized antibody) for HER2 overexpressing breast cancer [19], [20]. The gene discussed is ERBB2; the disease is breast carcinoma.